~~<i id='C97F67E5A6'><strike id='C97F67E5A6'><tt id='C97F67E5A6'><pre id='C97F67E5A6'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-08-07 04:36:03 Page View：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： CRISPR base editing slashes cholesterol levels in monkeys
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

explore

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Paxlovid study fails to answer questions over benefit for broader groups

KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Flu, Covid vaccination rates decline, new survey data show

JustinSullivan/GettyImagesVaccinationratesagainstfluandCovid-19havedeclinedsinceearlierinthepandemic